New Horizons in the Management of Advanced Epithelial Ovarian Cancer - Volume II

Building on the success of “New Horizons in the Management of Advanced Epithelial Ovarian Cancer”, we are pleased to launch this Volume II.Advanced epithelial ovarian cancer is a critical focus within gynaecologic oncology, as it continues to pose significant clinical challenges due to frequent late diagnosis, poor long-term prognosis, and the emergence of drug resistance. Recent years have witnessed notable progress in surgical interventions and systemic therapies, yet the overall survival rates remain unsatisfactory for patients with advanced disease.The advent of molecular characterization techniques, precision medicine, and targeted agents such as PARP inhibitors and antibody–drug conjugates (ADCs) has ushered in a new era of potential therapies. However, the heterogeneity of responses, evolving mechanisms of resistance, and a limited repertoire of validated predictive biomarkers underscore the complexity of effective disease management. Ongoing debates focus on the best strategies for integrating emerging agents, refining patient selection, and optimizing combination approaches to improve both treatment efficacy and patient outcomes.Antibody–drug conjugates (ADCs) are emerging as a therapeutic strategy to overcome resistance to currently available treatments and to reshape both induction and maintenance approaches. Building on this, Volume II emphasizes the identification of novel therapeutic targets, the development and clinical testing of new ADCs and targeted agents, and the integration of these strategies into personalized treatment algorithms. A central aim is to explore how innovative therapies may improve disease control while preserving tolerability and quality of life, thereby balancing therapeutic efficacy with patient-centred outcomes.This Research Topic aims to advance the understanding and management of advanced epithelial ovarian cancer by spotlighting innovative strategies and novel therapeutic modalities. Key objectives include elucidating mechanisms underpinning therapy resistance, identifying actionable therapeutic targets, and evaluating the clinical impact of combining novel agents such as ADCs and selective receptor modulators. It seeks to address how integrative molecular and genomic profiling can inform therapeutic decisions, as well as how multidisciplinary and patient-centred approaches can enhance care and quality of life. By synthesizing translational and clinical research, this collection strives to move the field toward more individualized, durable, and effective treatment strategies.The scope of this Research Topic encompasses original research and review articles that address frontier developments and persistent challenges in the management of advanced epithelial ovarian cancer. Submissions may include translational studies, clinical trials, and cutting-edge reviews. To gather further insights into the evolving landscape of advanced EOC, we welcome articles addressing, but not limited to, the following themes:• Antibody–drug conjugates (ADCs) and other emerging drug modalities • Novel therapeutic targets and target discovery • Novel and predictive biomarkers to guide patient selection • Mechanisms and management of resistance to current and novel therapies • Translational models and drug development pipelines • New combination strategies to optimize both induction (attack) and maintenance treatment • Clinical implementation of molecular and genomic profiling • Innovations in surgical and perioperative management • Integration of patient-centred and quality-of-life approaches into treatment planningWe welcome original research articles, reviews, clinical trials, translational studies, and perspectives. Topic editors: Orazio De Tommasi, Giulio Bonaldo, Roberto Tozzi Source: https://www.frontiersin.org/research-topics/81460/new-horizons-in-the-management-of-advanced-epithelial-ovarian-cancer---volume-ii